- Home
- GRAL vs PCRX Comparison
GRAL vs PCRX Comparison
Compare GRAL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- PCRX
- Stock Information
- Founded
- GRAL 2016
- PCRX 2006
- Country
- GRAL United States
- PCRX United States
- Employees
- GRAL N/A
- PCRX N/A
- Industry
- GRAL
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- GRAL
- PCRX Health Care
- Exchange
- GRAL NYSE
- PCRX Nasdaq
- Market Cap
- GRAL 610.9M
- PCRX 1.2B
- IPO Year
- GRAL N/A
- PCRX 2011
- Fundamental
- Price
- GRAL $30.32
- PCRX $26.09
- Analyst Decision
- GRAL Hold
- PCRX Buy
- Analyst Count
- GRAL 2
- PCRX 10
- Target Price
- GRAL $16.00
- PCRX $29.30
- AVG Volume (30 Days)
- GRAL 1.1M
- PCRX 892.8K
- Earning Date
- GRAL 02-15-2025
- PCRX 02-27-2025
- Dividend Yield
- GRAL N/A
- PCRX N/A
- EPS Growth
- GRAL N/A
- PCRX N/A
- EPS
- GRAL N/A
- PCRX N/A
- Revenue
- GRAL $117,669,000.00
- PCRX $694,957,000.00
- Revenue This Year
- GRAL $32.48
- PCRX $5.14
- Revenue Next Year
- GRAL $14.72
- PCRX $2.44
- P/E Ratio
- GRAL N/A
- PCRX N/A
- Revenue Growth
- GRAL 111.83
- PCRX 4.40
- 52 Week Low
- GRAL $12.33
- PCRX $11.16
- 52 Week High
- GRAL $32.65
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- PCRX 77.75
- Support Level
- GRAL N/A
- PCRX $25.06
- Resistance Level
- GRAL N/A
- PCRX $27.10
- Average True Range (ATR)
- GRAL 0.00
- PCRX 1.45
- MACD
- GRAL 0.00
- PCRX 0.28
- Stochastic Oscillator
- GRAL 0.00
- PCRX 86.23
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.